Biotech firm City Therapeutics has announced plans to list on the U.S. stock market through an initial public offering, joining a wave of recent biotechnology companies seeking public listings. The move comes amid a broader surge in biotech IPO activity, reflecting strong investor interest in the sector. With growing demand for innovative medical treatments and therapies, the company aims to raise capital for further research and development. Analysts suggest the trend highlights confidence in biotech’s potential for high returns, though market volatility remains a key consideration.
City Therapeutics files for US IPO as biotech listings surge Reuters
